Executives from Biotrial will speak at the third AGAH (Association for Applied Human Pharmacology)/Club Phase I Joint Annual Meeting, from 28-29 April in Lyon, France.
The two-day conference will elaborate on the theme of Managing Challenges in Early Drug Development: Biologicals and Small Molecules.
It will address how sponsors, investigators, regulatory authorities and ethics committees are adapting to the challenges raised by the first administration of a compound to a human subject.
Biotrial executives will be speaking on various topics, such as the accreditation of Phase I units in France, stopping criteria in first-in-man studies, and drug-drug interaction study design, with special focus on transporters.
